- Home
- LAC vs MYGN Comparison
LAC vs MYGN Comparison
Compare LAC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAC
- MYGN
- Stock Information
- Founded
- LAC 2023
- MYGN 1991
- Country
- LAC Canada
- MYGN United States
- Employees
- LAC N/A
- MYGN N/A
- Industry
- LAC Metal Mining
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LAC Basic Materials
- MYGN Health Care
- Exchange
- LAC Nasdaq
- MYGN Nasdaq
- Market Cap
- LAC 666.1M
- MYGN 744.7M
- IPO Year
- LAC N/A
- MYGN 1995
- Fundamental
- Price
- LAC $2.68
- MYGN $7.64
- Analyst Decision
- LAC Hold
- MYGN Hold
- Analyst Count
- LAC 7
- MYGN 16
- Target Price
- LAC $4.41
- MYGN $20.17
- AVG Volume (30 Days)
- LAC 4.2M
- MYGN 1.0M
- Earning Date
- LAC 05-12-2025
- MYGN 05-06-2025
- Dividend Yield
- LAC N/A
- MYGN N/A
- EPS Growth
- LAC N/A
- MYGN N/A
- EPS
- LAC N/A
- MYGN N/A
- Revenue
- LAC N/A
- MYGN $837,600,000.00
- Revenue This Year
- LAC N/A
- MYGN $2.99
- Revenue Next Year
- LAC N/A
- MYGN $8.36
- P/E Ratio
- LAC N/A
- MYGN N/A
- Revenue Growth
- LAC N/A
- MYGN 11.21
- 52 Week Low
- LAC $2.02
- MYGN $7.35
- 52 Week High
- LAC $5.20
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- LAC 47.48
- MYGN 28.54
- Support Level
- LAC $2.60
- MYGN $7.69
- Resistance Level
- LAC $2.83
- MYGN $8.27
- Average True Range (ATR)
- LAC 0.21
- MYGN 0.56
- MACD
- LAC 0.01
- MYGN 0.04
- Stochastic Oscillator
- LAC 67.27
- MYGN 17.37
About LAC Lithium Americas Corp.
Lithium Americas is a pure-play lithium producer. The firm owns 62% of one resource, Thacker Pass, that is located in northwest Nevada, with automaker General Motors owning the remaining 38%. Thacker Pass recently began construction and is expected to begin production in the mid- to late 2020s. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.